94.9%
EntrestoBeta BlockersSGLT-2 Inhibitorscancer therapyQueen Elizabeth Hospitalhaematological malignancyIBM CorpEuropean Society of Cardiology
…of ACE-Inhibitors / ARBs, Beta Blockers, SGLT-2 Inhibitors, and Entresto at follow-up, compared to baseline (* = p-value < 0.05). ACE-I,…